13 results about "Mercaptopurine" patented technology

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

The application discloses a preparation method of copper-6-mercaptopurine metal organic gel and application thereof in perfluorooctyl sulfonic acid detection, and belongs to the technical field of optical sensing, wherein the preparation method takes 6-mercaptopurine as a reducing agent and a complexing agent, and prepares copper-6-mercaptopurine metal organic gel through a hydrothermal method. The copper-6-mercaptopurine metal organic gel prepared by the application has very high peroxidase-like activity, can efficiently catalyze a substrate 3,3',5,5'-tetramethylbenzidine (TMB) to generate an oxidation product TMB (oxTMB) in the presence of H2O2, and thus can be used as a novel peroxide mimicking nano-enzyme. The application also discloses a colorimetric sensor based on the above copper-6-mercaptopurine metal organic gel and used for perfluorooctyl sulfonic acid detection.

The utility model provides a full-automatic rotary tabletting device for mercaptopurine tablets, which belongs to the technical field of pharmaceutical equipment, and comprises a tabletting case, a control case arranged at the bottom of the tabletting case, a case cover arranged at the top of the tabletting case, a blanking hopper arranged at the top of the case cover, a die assembly arranged in the tabletting case, a feeding mechanism, a discharging mechanism and a control mechanism, the feeding mechanism is arranged at the bottom of the discharging hopper; the tablet pressing mechanism is arranged in the tablet pressing machine box; and the sheet discharging mechanism is arranged in the mold assembly. Through the arrangement of the tablet discharging mechanism, mercaptopurine tablets can be discharged while cleaning and dust collection can be carried out on the tablet pressing rotary chamber and the rotary table, residual powder and scraps generated in the tablet pressing process are removed in time, cleanliness of a tablet pressing area is kept, accumulated dust in the structure is reduced, and the service life of the device is prolonged; production interruption caused by dust blockage is reduced, continuous operation of a production line is guaranteed, and production efficiency is improved.

The present invention discloses a mercaptopurine microtablet, its preparation method, and application. The mercaptopurine microtablet has a diameter of 2 to 3 mm and a diameter-to-thickness ratio of 0.85 to 1.15. It comprises the following components, calculated by weight: 15 to 30 parts of a mercaptopurine API; 40 to 80 parts of a filler; 3 to 8 parts of a binder; 1 to 3 parts of a lubricant; and 1 to 3 parts of a disintegrant. The D90 particle size of the mercaptopurine API is 40 to 125 μm; and the D50 particle size of the mercaptopurine API is 5 to 35 μm. The mercaptopurine microtablet of the present invention has excellent in vivo pharmacokinetic properties, good dissolution effect, excellent friability, hardness, and content uniformity. It is bioequivalent to the control tablet Purinethol in terms of absorption rate and extent, and has good application prospects in tumor treatment, especially in childhood acute lymphoblastic leukemia.

This disclosure relates to a liquid chromatography-mass spectrometry (LC-MS) method for simultaneously detecting the concentrations of six immunosuppressants. The LC-MS method includes: (1) preparing a standard solution and detecting the standard solution using LC-MS to establish a standard curve; wherein the six immunosuppressants are azathioprine, 6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine, 6-thioguanine nucleoside, and imidazolidin; (2) detecting the sample to be tested using LC-MS, and determining the content of the six immunosuppressants in the sample based on the detection results and the standard curve. The detection method provided by this disclosure can determine the content of six immunosuppressants in a single injection, with a short detection time (resulting within 5 minutes), improving detection efficiency while reducing operational difficulty, and is suitable for high-throughput sample detection.

This invention discloses a medicament for inhibiting the formation of thorns in Sichuan pepper, relating to the field of Sichuan pepper cultivation technology. The medicament comprises the following components at final concentrations: lovastatin 5-20 mg / L, 6-mercaptopurine 5-10 mg / L, pyrimidinol 10-30 mg / L, proline 20-100 mg / L, glycine 20-100 mg / L, glutamic acid 20-100 mg / L, potassium dihydrogen phosphate 5-7 mg / L, sucrose 5-7 mg / L, and Tween-80 1-2 mg / L. This invention also provides a method for preparing the medicament for inhibiting the formation of thorns in Sichuan pepper. This invention reduces the incidence of thorns in Sichuan pepper, with a significant thorn-inhibiting effect. While inhibiting thorn formation, it also increases the growth of new shoots in Sichuan pepper, effectively solving the problem that single-hormone inhibitors easily lead to excessive shoot growth, decreased flower bud differentiation rate, or reduced fruit weight.

The disclosure relates to a method for eliminating interference of theophylline in immunoassay and an immunodetection kit. The method for eliminating interference of theophylline in immunoassay includes: performing an immunoassay in the presence of a theophylline interference-resistant agent, the theophylline interference-resistant agent having a final concentration of 0.1 mg / mL-100 mg / mL, and being selected as at least one component from a group consisting of free 6-mercaptopurine, 6-thioguanine, 8-azguanine, hypoxanthine, adenine, purine, 2,6,8-trioxypurine, adenine nucleotide, and adenosine. The method and the kit can effectively reduce interference of theophylline on immunoassay results.

The present invention belongs to the field of chemical analysis and testing, and particularly relates to a fluorescent probe based on a double-bond structure and its application. First, using 4-aminostyrene and 7-(diethylamino)coumarin-3-carboxylic acid as raw materials, dichloromethane as a solvent, and 1-hydroxybenzotriazole (HOBT) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) as condensing agents, the final product crude is obtained by stirring at room temperature. The obtained crude product is then separated by column chromatography using petroleum ether and ethyl acetate as eluents to obtain the final yellow pure product. The fluorescent probe obtained by the present invention has good optical properties and fluorescence selectivity for 6-mercaptopurine (6-MP), and can realize the fluorescence detection of 6-MP.

Various embodiments relate to compounds, having structures according to Structure A or Structure B, as specified herein. The compounds according to various embodiments may inhibit NT5C2 nucleotidase. The compounds according to various embodiments may synergistically decrease cell viability of NT5C2 R367Q mutant lymphoblasts when used in combination with 6-mercaptopurine (6-MP) to treat a cancer. The cancer may be, but is not limited to, acute lymphoblastic leukemia. Various embodiments relate to a compositions that may include one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof and a pharmaceutically acceptable carrier. Various embodiments relate to methods of treating cancer. The method may comprise administering a therapeutically effective amount of one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof.

This invention relates to a method for simultaneously detecting the concentrations of six immunosuppressants in blood. The method includes: (1) preparing a standard solution and detecting the standard solution using liquid chromatography-mass spectrometry to establish a standard curve; wherein the six immunosuppressants are azathioprine, 6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine, 6-thioguanine nucleoside, and imidazolidin; (2) mixing the blood sample to be treated, internal standard working solution, and protein precipitant, and diluting the supernatant to obtain the sample to be injected; (3) detecting the sample to be injected using liquid chromatography-mass spectrometry, and determining the content of the six immunosuppressants in the blood sample to be treated based on the detection results and the standard curve. The detection method provided by this invention can determine the content of six immunosuppressants in a single injection, with a short detection time, producing results within 5 minutes, improving detection efficiency while reducing operational difficulty, and is suitable for high-throughput sample detection.

The invention discloses a mercaptopurine micro-tablet as well as a preparation method and application thereof. The diameter of the mercaptopurine microchip is 2 to 3mm; the ratio of the diameter to the thickness is 0.85 to 1.15; comprising the following components in parts by weight: 15-30 parts of mercaptopurine bulk drug; 40 to 80 parts of a filling agent; 3-8 parts of an adhesive; 1-3 parts of a lubricant; 1-3 parts of a disintegrating agent; the D90 particle size of the mercaptopurine bulk drug is 40 [mu] m-125 [mu] m; the D50 particle size of the mercaptopurine bulk drug is 5-35 [mu] m. The mercaptopurine micro-tablet disclosed by the invention is excellent in in-vivo pharmacokinetic performance, good in dissolution effect and excellent in friability, hardness and content uniformity; the absorption speed and the absorption degree of the pharmaceutical composition are bioequivalent to those of a tablet Purinethol serving as a control preparation, and the pharmaceutical composition has a good application prospect in tumor treatment, especially in the aspect of acute lymphocytic leukemia of children.

The invention provides an electroplating cobalt plating solution for filling an X-type through hole of a printed circuit and application, the electroplating cobalt plating solution is used for the printed circuit and comprises cobalt sulfate heptahydrate, boric acid, sodium sulfate and sodium chloride, and an additive comprises one or more of adenine nucleoside, adenine, 6-mercaptopurine, 2-thioxanthine and 6-chloropurine. The high-quality filling effect is achieved, meanwhile, the average thickness increase of the surface cobalt is controlled to be smaller than 2 micrometers, the depression degree is controlled to be smaller than 2 micrometers, and the filling degree and the surface cobalt thickness control capacity are in the leading position in the similar invention and the existing production technology.

The invention discloses a preparation method of a transdermal self-assembly nanomedicine: by the self-assembly site reaction of 6-mercaptopurine and zinc acetate, programmed death receptor 1 is added to the reaction system, and the self-assembly nanomedicine 6-MP / Zn / PD-1 loaded with 6-MP and PD-1 is prepared; Arginine-rich dendrimer (GR) is modified on the surface to prepare a transdermal self-assembly nanomedicine 6-MP / Zn / PD-1 / GR with transdermal ability; 6-MP / Zn / PD-1 / GR can also be incorporated into a gel for transdermal administration. The preparation method provided by the present invention is extremely simple, and the transdermal self-assembly nanomedicine prepared simultaneously coats therapeutic antibodies therein, achieves the synergistic treatment of chemotherapy and immunity, and can achieve transdermal administration, which can be applied to prepare a drug for transdermal administration and can effectively deliver drugs through the skin.